Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Mumps-Measles-Rubella vaccine (MMR)

Generic name
Mumps-Measles-Rubella vaccine (MMR)
Brand name
ATC Code
J07BD52

Pharmacokinetics in children

No information

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Measles-mumps-rubella (MMR) vaccination
  • Subcutaneous
    • 14 months
      [1]
      • NATIONAL VACCINATION PROGRAMME: First vaccination 0.5 ml/dose, once only.
    • 9 years
      [1]
      • NATIONAL VACCINATION PROGRAMME 2nd vaccination 0.5 ml/dose, once only.
    • 9 months up to 12 months
      [1] [2] [3] [4]
      • 0.5 ml/dose, once only.
      • In certain cases it may be desirable to give the BMR vaccination earlier, for example in outbreak situations, day care or a trip to a region where measles is frequent. The National Vaccination Program indicates that this can be done from 6 months of age. Children who are vaccinated before the age of 12 months should be vaccinated again at the age of 12-15 months.

  • Intramuscular
    • 14 months
      [1]
      • NATIONAL VACCINATION PROGRAMME: first vaccination 0.5 ml/dose once only

    • 9 years
      [1]
      • NATIONAL VACCINATION PROGRAMME: second vaccination 0.5 ml/dose once only

    • 9 months up to 12 months
      [1] [2] [3] [4]
      • 0.5 ml/dose, once only.
      • In certain cases it may be desirable to give the BMR vaccination earlier, for example in outbreak situations, day care or a trip to a region where measles is frequent. The National Vaccination Program indicates that this can be done from 6 months of age. Children who are vaccinated before the age of 12 months should be vaccinated again at the age of 12-15 months.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children aged 9–12 months sometimes have an inadequate response to the vaccine due to circulating maternal antibodies and / or insufficient development of the immune system. However, it may be necessary to vaccinate, eg in outbreak situations, day care or when traveling to a region where measles is common.

If the vaccine is to be given simultaneously with another injectable vaccine, always administer the vaccines at different injection sites. In other cases, maintain an interval of at least four weeks.

Live vaccines (such as the BMR vaccine) should not be administered to infants exposed to infliximab in utero until 12 months after birth. Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless serum levels of infliximab are undetectable in the infant. These infants may be at increased risk for infection, including severe disseminated infection that may become fatal. [DHPC]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. RijksInstituut voor Volksgezondheid en Milieu (RIVM), Rijksvaccinatieprogramma: vaccinatieschema versie 1.0 , https://rijksvaccinatieprogramma.nl/documenten/rvp-richtlijn-uitvoering-rvp-2020, 18 dec 2020
  2. MSD VACCINS, SmPC MMRVaxpro (EU/1/06/337) Rev 26, 04-12-2020, www.emea.europa.eu
  3. GlaxoSmithKline BV, SPC Priorix, RVG 22052 (geraadpleegd 23 okt 2009), www.cbg-meb.nl, http://db.cbg-meb.nl/IB-teksten/h22052.pdf
  4. GlaxoSmithKline BV, SPC Priorix, RVG 22052 (geraadpleegd 23 okt 2009), www.cbg-meb.nl, http://db.cbg-meb.nl/IB-teksten/h22052.pdf
  5. Representatives of marketing authorisation holders of infliximab, DHPC Infliximab 07 maart 2022,, https://www.cbg-meb.nl/documenten/brieven/2022/03/08/dhpc-infliximab

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes